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Background: In Gaucher disease (GD), resulting from mutations in the GBA gene, mutant β-glucocerebrosidase
(GCase) molecules are recognized as misfolded in the endoplasmic reticulum (ER). They are retrotranslocated to the
cytoplasm, where they are ubiquitinated and undergo proteasomal degradation in a process known as the ER
Associated Degradation (ERAD). We have shown in the past that the degree of ERAD of mutant GCase correlates
with GD severity.
Persistent presence of mutant, misfolded protein molecules in the ER leads to ER stress and evokes the unfolded
protein response (UPR).
Methods: We investigated the presence of UPR in several GD models, using molecular and behavioral assays.
Results: Our results show the existence of UPR in skin fibroblasts from GD patients and carriers of GD mutations.
We could recapitulate UPR in two different Drosophila models for carriers of GD mutations: flies heterozygous for
the endogenous mutant GBA orthologs and flies expressing the human N370S or L444P mutant GCase variants. We
encountered early death in both fly models, indicating the deleterious effect of mutant GCase during development.
The double heterozygous flies, and the transgenic flies, expressing mutant GCase in dopaminergic/serotonergic
cells developed locomotion deficit.
Conclusion: Our results strongly suggest that mutant GCase induces the UPR in GD patients as well as in carriers of
GD mutations and leads to development of locomotion deficit in flies heterozygous for GD mutations.
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Gaucher disease (GD) is a lysosomal storage disease,
caused by mutations in the gene encoding lysosomal
acid β-glucocerebrosidase (GCase), designated GBA. As
a result, glucosylceramide (GlcCer) is not properly de-
graded and accumulates primarily in cells of mono-
nuclear phagocyte origin [1,2].
More than 300 mutations were identified in the GBA
gene. A large fraction of them are missense mutations,
though premature termination, splice site mutations,
deletions and recombinant alleles have been recognized
as well [3]. There are several abundant mutations. Thus,
the N370S mutation [4] is the most prevalent among
type 1 GD patients, while the L444P mutation [5] is
most common among the neuronopathic types of GD.* Correspondence: horwitzm@post.tau.ac.il
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reproduction in any medium, provided the orThe majority of patients homozygous for this mutation
develop type 3 GD. The 84GG mutation is an insertion
of a guanine 84 nucleotides downstream from the first
initiator methionine of the GBA mRNA, resulting in
premature protein termination [6].
As a lysosomal enzyme, GCase is synthesized on endo-
plasmic reticulum (ER) bound polyribosomes [7]. Upon
its entry into the ER, it undergoes N-linked glycosylation
on four asparagines, after which it is subject to ER qual-
ity control (ERQC). When correctly folded it shuttles to
the Golgi compartment for further modifications on the
N-glycans and finally it traffics to the lysosomes. Mutant
GCase variants are recognized as misfolded proteins and
undergo various degrees of ER associated degradation
(ERAD). The accumulation of misfolded molecules in
the ER, activate signaling events known as the unfolded
protein response (UPR) [8]. UPR monitors the condi-
tions in the ER, by sensing insufficiency in proteintd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expression [9]. The ER membrane harbors three ER
stress sensors: The type 1 transmembrane protein kinase
endoribonuclease IRE1, the type 1 protein kinase PERK,
and the activating transcription factor 6 (ATF6). These
three branches operate simultaneously and use unique
mechanisms of signal transductions. The three UPR trans-
ducers are constitutively expressed in metazoan cells [10],
and are maintained in an inactive state through interaction
with the ER protein chaperone BiP. Accumulated unfolded
protein(s) binds and sequesters BiP, thus promoting BiP
dissociation from PERK, IRE1 and ATF6. Dissociation of
BiP from the three stress sensors allows their modification
and signal transduction, which results in a response to the
accumulation of misfolded proteins [11]. Thus, IRE1 under-
goes dimerization and phosphorylation and participates in
a cytoplasmic complex, which splices the transcription fac-
tor X-box binding protein 1 (Xbp1). Upon its splicing the
Xbp1 mRNA is translated into a protein that translocates
into the nucleus and turns on UPR related genes [9,12,13].
PERK is a kinase that undergoes dimerization and auto-
phosphorylation and mediates phosphorylation of the
eukaryotic translation initiation factor 2α (eIF2α). Phos-
phorylated eIF2α attenuates general protein translation in
the cells [9,11,14]. ATF6, the third component among the
UPR sensors, shuttles to the Golgi, where it is sequentially
cleaved by proteases. Its cleaved N-terminal cytosolic frag-
ment enters the nucleus where it serves as a transcription
factor of UPR upregulated genes, including the induction of
the proapoptotic bZIP transcription factor CCAAT/en-
hancer-binding protein homologous protein (CHOP) [15],
which is essential for cell cycle arrest and the apoptotic
response to chronic ER stress [9,11,13,14,16]. Manifestation
of UPR in GD derived cells has already been noted in cell
lines that originated from GD patients, homozygous for the
N370S or the L444P mutations [17,18]. Yet, accumulation
of glucosylceramide (GlcCer) per se, induced by con-
duritol-β-epoxide (CBE), did not result in UPR [19]. Like-
wise, in the absence of mutant GCase there was no UPR
[19], underscoring the importance of mutant GCase in the
activation of ERAD and UPR.
In this study we tested whether UPR is activated in
GD. Our results show the occurrence of UPR in GD
derived skin fibroblasts and in carriers of GD mutations,
both in humans and Drosophila. In heterozygous flies,
and flies expressing the human N370S or L444P mutant
GCase variants there were significant developmental
defects. Locomotion deficit was evident in aging flies,
reminiscent of Parkinson disease (PD).
Materials and methods
Materials
The following primary antibodies were used in this study:
rabbit polyclonal anti-GRP78 antibodies (Cell SignalingTechnology, Beverly, MA, USA), mouse monoclonal anti-
CHOP antibody (Cell Signaling Technology, Beverly, MA,
USA), rabbit polyclonal anti-phospho-eIF2α (Ser51) anti-
bodies, rabbit polyclonal anti-eIF2α antibodies (from cell
signaling Technology, Beverly, MA, USA), mouse mono-
clonal anti-actin antibody (Sigma-Aldrich, Israel), rabbit
polyclonal anti human GCase antibodies (Sigma-Aldrich,
Israel) and mouse monoclonal anti-tubulin antibody
(Sigma-Aldrich, Israel).
Secondary antibodies used were: horseradish peroxidase-
conjugated goat anti-mouse antibodies and Horseradish
peroxidase-conjugated goat anti-rabbit antibodies (both
from Jackson Immuno Research Laboratories, West
Grove, PA, USA). Leupeptin, phenylmethylsulfonyl fluo-
ride (PMSF) and aprotinin were from Sigma–Aldrich
(Rehovot, Israel). Absolute Blue qPCR SYBR Green ROX
Mix was from Thermo Scientific (Logan, UT, USA).
Cell lines
Human primary skin fibroblasts were provided by two
publically available, sources: by “Cell Line and DNA
Biobank from Patients Affected by Genetic Diseases”
(G. Gaslini Institute), Telethon Genetic Biobank for GD
skin fibroblasts or by Prof. R. O. Brady, NIH. The pa-
tients signed an informed consent. Work with the cell
lines was in accordance with the institutional guidelines
of Tel Aviv University. Identifiable clinical and personal
data from the patients were not available for this study.
Cells were grown in DMEM supplemented with 20%
FBS (Biological Industries, Beit Haemek, Israel). All cells
were grown at 37°C in the presence of 5% CO2.
Fly strains
Canton-S flies (WT) served as a wild-type control.
Strains were maintained on cornmeal-molasses me-
dium at 25°C. Strains harboring a minos transposable
element in CG31414 [Mi{ET1}CG31414] or in CG31148
[Mi{ET1}CG31148] were from the Bloomington Stock Cen-
ter (#23602 and #23435, respectively). Da-Gal4 and Ddc-
Gal4 driver lines were obtained from Bloomington Stock
Center. Transgenic flies, harboring pUASTmycHisGCase,
pUASTmycHisN370SGCase or pUASTmycHisL444PGCase
on the second chromosome, were established by BestGene
(Chino Hills, CA, USA).
Methods
Construction of plasmids
An XbaI-SapI fragment, isolated from pcDNA4 (Invitrogen
Life Technologies Co., Carlsbad, CA, USA) was subcloned
between XbaI and SapI restriction sites of pUAST, to
create pUASTmycHis. EcoRI-XhoI fragments, containing
either the normal or the N370S or the L444P mutant
human GCase cDNAs, isolated from the plasmids MycHis
WT GCase, MycHis N370S GCase or MycHis L444P

















The table contains the sequence of all the primers used in this work.
RT real time, R reverse, F forward.
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Total RNA was isolated using EZ-RNA kit (Biological
Industries, Beit Haemek, Israel), according to the manu-
facturer’s instructions. For RNA extraction from flies,
adult flies were frozen in liquid nitrogen and then
homogenized in TRI Reagent solution (MRC, Cincinnati,
Ohio, USA). The extraction was performed according to
the manufacturer’s recommendations.
RT PCR
Two μg of RNA were reverse transcribed with M-MLV
reverse transcriptase (Promega Corporation, CA, USA),
using oligo dT primer in a total volume of 20 μl, at 42°C
for 60 minutes. Reactions were stopped by incubation at
70°C for 15 minutes. One-two microliters of the resul-
ting cDNA were amplified by PCR or by quantitative
real time PCR.
PCR
PCR was executed in 25 μl containing 0.4 mM dNTPs,
10 ρM of each primer, 1 unit of Taq polymerase (Takara,
Shiga, Japan) and 10× Taq buffer (10 mM Tris HCL
pH 8.3, 50 mM KCl and 1.5 mM MgCl2). Thirty cycles
of 94°C (1 minute), 58°C (1 minute) and 72°C (1 minute)
were performed, following by 10 minutes at 72°C for
final extension. PCR reactions were carried out in an
Eppendorff Master-cycler EP Gradient S (Eppendorf,
Hamburg, Germany). PCR products were separated by
agarose gel electrophoresis (1–1.5%) and visualized with
0.1% ethidium bromide. Sequence of the primers used
appears in Table 1.
Quantitative real time PCR
One μl of cDNA was used for quantitative real time
PCR. PCR was performed using “power SYBR green
QPCR mix reagent kit” (Applied Biosystems, Foster City,
CA, USA) by Rotor-Gene 6000 (Qiagen, Valencia, CA,
USA). The reaction mixture contained 50% QPCR mix,
300 nM of forward primer and 300 nM of reverse
primer, in a final volume of 10 μl. Thermal cycling con-
ditions were 95°C (10 minutes), and 40 cycles of 95°C
(10 seconds) 60°C (20 seconds) and 72°C (20 seconds).
Relative gene expression was determined by Ct value.
Human cDNA was amplified with primers specific for
human BiP (Human-GRP78-RT-F and Human-GRP78-
RT-R, Table 1) or human CHOP (Human-CHOP-RT-F
and Human-CHOP-RT-R, Table 1). GAPDH was used as
a normalizing control for human genes (amplified with
primers: Human-GAPDH-RT-F and Human-GAPDH-RT-R, Table 1). Amplification of Drosophila genes was
conducted with primers specific for Drosophila Hsc-70-3
(Drosophila-Hsc-70-3-RT-F and Drosophila-Hsc-70-3-
RT-R, Table 1), or for the spliced form of Drosophila
Xbp1 (Drosophila-s-Xbp1-RT-F and Drosophila-s-Xbp1-
RT-R, Table 1). RP49 was used as a normalizing control
(amplified with primers: Drosophila RP49-RT-F and
Drosophila RP49-RT-R, Table 1).Detection of spliced Xbp1 mRNA processing
Human spliced Xbp1 was amplified from cDNA using the
primers: Human s-Xbp1 F and Human s-Xbp1-R (Table 1).
GAPDH was used as a normalizing control (amplified
with primers: Human-GAPDH-F and Human-GAPDH-R,
Table 1). To amplify Drosophila spliced Xbp1 the primers:
Drosophila s-Xbp1-RT-F and Drosophila s-Xbp1-RT-R
(see Table 1) were used, with Drosophila RP49 as a nor-
malizing control. The forward primer could anneal only to
the spliced form of Xbp1 mRNA.SDS-PAGE and western blotting
Cultured cells
Cell monolayers were washed three times with ice-cold
phosphate-buffered saline (PBS) and lysed at 4°C in lysis
buffer (10 mM HEPES pH 8.0, 100 mM NaCl, 1 mM
MgCl2 and 1% Triton X-100) containing 10 μg/ml apro-
tinin, 0.1 mM phenylmethylsulfonyl fluoride (PMSF) and
10 μg/ml leupeptin. Lysates were incubated on ice for
30 minutes and centrifuged at 10,000 g for 15 minutes
at 4°C.
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For each preparation, 10 flies were homogenized in RIPA
lysis buffer (50 mM Tris/HCL, 150 mM NaCl, 1 mM
EDTA, 1% TritonX-100, 1% sodiumdeoxycholate, 0.1%
SDS) containing protease inhibitors (10 μg/ml leupeptin,
10 μg/ml aprotinin and 0.1 mM PMSF- all from Sigma-
Aldrich, Israel). Samples containing the same amount of
protein were electrophoresed through 10% SDS–PAGE
and electroblotted onto a nitrocellulose membrane
(Schleicher and Schuell BioScience, Keene, NH, USA).
Further treatment of membranes and ECL detection was
as described elsewhere [21].
Enzymatic activity
Confluent primary skin fibroblasts were washed twice with
ice-cold PBS and collected with a rubber policeman in
150 μl sterile water. Cell lysates, containing 40 μg of pro-
tein, were assayed for GCase activity in 0.2 ml of 100 mM
potassium phosphate buffer, pH 4.5, containing 0.15%
Triton X-100 (Sigma-Aldrich, Israel) and 0.125% tauro-
cholate (Calbiochem, La Jolla, CA, USA) in the presence
of 1.5 mM 4-methyl-umbeliferyl-glucopyranoside (MUG)
(Genzyme Corporation. Boston, MA, USA) for 1 h at 37°C.
The reaction was stopped by the addition of 0.5 ml of stop
solution (0.1 M glycine, 0.1 M NaOH, pH 10) and the
amount of 4-methyl-umbeliferone (4-MU) was quantified
using Perkin Elmer Luminescence Spectrometer LS 50
(excitation wavelength: 340 nm; emission: 448 nm) [22].
Endonuclease-H (endo-H) treatment
Samples of cell lysates, containing 100 μg of total pro-
tein, were subjected to an overnight incubation with
endo-H (New England Biolabs, Beverly, MA, USA),
according to the manufacturer’s instructions. They were
electrophoresed through 10% SDS-PAGE and the corre-
sponding blot was interacted with anti GCase and anti
actin antibodies. Total GCase amount was divided by
that of actin at the same lane and normalized to WT
GCase, which was considered 100. To determine the
endo-H resistant fraction, the intensity of GCase resist-
ant fraction was divided by the intensity of the entire
amount of GCase in the same lane. GDPV (GD Predict-
ive Value) was determined as described elsewhere [23]
(GCase amount X GCase resistant fraction: 100).
Climbing assay of flies
Vials, each containing 10 male flies, were tapped gently
on the table and left standing for 15 seconds. The num-
ber of flies that climbed at least five cm was recorded.
The experiment was repeated 10 times.
Blot quantitation
The blots were scanned using Image Scan scanner
(Amersham Pharmacia Biotech, Buckinghamshire, England),and the intensity of each band was measured by the
Image Master 1DPrime densitometer (Amersham
Pharmacia Biotech, Buckinghamshire, England) and
GelQuant (BiochemLabSolutions).
Statistics
All the results were statistically analyzed using the
student t-test.
Results
Activation of UPR in GD derived fibroblasts
Mutant GCase is recognized as misfolded in the ER.
After several unsuccessful attempts to refold it, it under-
goes ERAD [21]. The level of ERAD correlates with GD
severity, since it determines the amount of mutant
enzyme that reaches the lysosomes and degrades the
substrate there, depending on its residual activity. More-
over, skin fibroblasts that derived from GD patients
homozygous for the N370S or the L444P mutations
exhibited UPR [17,24]. We, therefore, decided to extend
the study and tested whether UPR is activated in add-
itional GD derived cells. The UPR induces increased
transcription of the molecular chaperone BiP and the
transcription factor CHOP [25]. In addition, the UPR
induces splicing of the Xbp1 transcript and phosphoryl-
ation of eIF2α [25].
Based on the above, we first examined the activation
of UPR in GD by testing mRNA levels of BiP and CHOP
in skin fibroblasts obtained from GD patients. To do so,
we used the quantitative RT-PCR approach, using
normal fibroblasts as control. Our results, (Figure 1A),
showed a significant increase in BiP and CHOP mRNA
levels in GD derived fibroblasts, compared to normal
cells. A concomitant increase was detected in the pro-
tein levels of BiP and CHOP (Figure 1B-D).
In GD, there is accumulation of the GCase substrate
GlcCer, along with the presence of mutant GCase, which
undergoes ERAD. In order to test possible contribution
of substrate accumulation to UPR, we induced substrate
accumulation using the non-competitive inhibitor of
GCase, CBE, for 10 days, as has done by Farfel et al.
[19]. It has already been shown in the past that CBE
treatment leads to substrate accumulation in skin fibro-
blasts [26]. Treatment of normal skin fibroblasts with
200 μM CBE, which completely abolished GCase activ-
ity, (Additional file 1: Figure S1A) did not induce eleva-
tion in mRNA levels of either BiP or CHOP (Additional
file 1: Figure S1B). Thus, substrate accumulation in GD
derived fibroblasts does not activate the UPR.
Splicing of Xbp1 as a UPR marker in GD derived
fibroblasts
Splicing of Xbp1 is a central hinge of the IRE1 pathway
[25,27], which is another branch activated in the UPR.
Figure 1 Elevation in CHOP and BiP levels in GD derived cells. A. RNA was isolated from different GD derived skin fibroblasts, and the
corresponding cDNA was used for quantitative RT-PCR with primers specific for human BiP or CHOP. GAPDH was used as a normalizing control.
Two different normal cell lines were used as control. Dark box: CHOP; Light box: BiP. B, C. Protein lysates were prepared from different GD
derived skin fibroblasts and subjected to western blotting. The corresponding blots were interacted with anti BiP (B) and anti CHOP (C)
antibodies. As a loading control, the blots were interacted with anti-tubulin antibody. For each protein there are two blots, each with a normal
control. This is due to the fact that cell lysates were prepared at different times, depending on the growth rate of the cell lines and, therefore, ran
on different gels. The genotypes for B and C are shown in D. D. The blots were quantified as explained. The amount of BiP and CHOP was
divided by that of tubulin in the same lane, and the values obtained for normal cells were considered 1. The results are the mean (minus plus
standard error) of three different experiments. Significance: * < 0.05; ** < 0.01.
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frames, A and B. Under normal conditions, only A frame
is transcribed, producing an unspliced version of Xbp1
with no protein product (see Figure 2A) [28]. Upon UPR
activation, IRE1 dimerizes and participates in cyto-
plasmic splicing of Xbp1, thus, removing a 26 bp intron
from the Xbp1 mRNA. The spliced Xbp1 mRNA (frame
B) encodes a transcription factor that binds to the UPRE
or ERSE consensus sequences of promoters of UPR
target genes, thus leading to their transcription [28].
Expression of spliced Xbp1 in GD derived skin fibro-
blasts was tested (see Figure 2B). Our results, presented
in Figure 2B, showed that in GD derived fibroblasts the
spliced Xbp1 product was significantly elevated, in com-
parison to normal fibroblasts.
Elevation in phosphorylation of eIF2α in GD derived
fibroblasts
Dissociation of PERK from BiP leads to its dimerization
and autophosphorylation, and mediates phosphorylation
of the eukaryotic translation initiation factor 2α (eIF2α).eIF2α is a subunit of eIF2, a heterotrimeric GTPase,
required to bring the initiator methionyl-tRNA to the
40S ribosomal subunit for AUG initiation codon selec-
tion. Phosphorylation of eIF2α inhibits the GDP/GTP
exchange reaction on eIF2, thus preventing eIF2 recyc-
ling and its initial step of protein synthesis [9]. Phos-
phorylated eIF2α attenuates general protein translation
in cells [9,11,14]. We therefore tested possible changes
in the levels of phosphorylation of eIF2α, using western
blotting and interaction with anti-phosphorylated
eIF2α antibodies. Our results, presented in Figure 2D, E,
showed that eIF2α phosphorylation was increased in
GD derived fibroblasts in comparison to normal
fibroblasts.
Activation of UPR in carriers of GD mutations
Our results strongly suggested that UPR results from the
presence of mutant GCase in the cells, since substrate
accumulation by itself did not lead to activation of the
UPR machinery. To confirm our observations we
decided to investigate the occurrence of UPR in cells
Figure 2 Elevation in Xbp1 splicing and eIF2α phosphorylation in GD derived cells. A. Scheme showing the two Xbp1 RNA variants, the
spliced and the non-spliced forms. B. RNA was isolated from different GD derived skin fibroblasts, and the cDNA prepared from it was used for
RT-PCR, with primers specific for the spliced form of human Xbp1. GAPDH was used as a normalizing control. C. The results (three different
experiments) were quantified and the amount of Xbp1 was divided by that of GAPDH in the same lane. The values obtained for normal cells
were considered 1. D. Protein lysates were prepared from different GD derived skin fibroblasts and subjected to western blotting. The
corresponding blots were interacted with anti phosphorylated eIF2α (p-eIF2α) and as a loading control, with anti eIF2α antibodies. E. p-eIF2α
amount was divided by that of eIF2α in the same lane, and the values obtained for normal cells were considered 1. The results are the mean
(minus plus standard error) of three different experiments. Significance: * < 0.05; ** < 0.01. The genotypes for B and D are shown in C and
E, respectively.
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end we tested elevation in BiP and CHOP mRNA, in
Xbp1 splicing and in phosphorylation of eIF2α in cells
that derived from carriers of several GD mutations. Our
results, presented in Figure 3, showed a significant eleva-
tion in the amount of BiP and CHOP mRNAs as well as
in Xbp1 splicing in carriers of GD mutations. Likewise,
phosphorylation of eIF2α increased significantly in cells
that originated from carriers in comparison to normal
cells. Interestingly, we observed activation of UPR also
in cells carrying the 84GG mutation, strongly suggesting
that existence of a mutant GBA mRNA evokes UPR.
Activation of UPR in Drosophila GD-like carriers
There are two GBA homologs in Drosophila, designated
CG31414 and CG31148, both encoding proteins show-
ing ~31% identity and ~49% similarity to the human
GCase. Two Drosophila strains are available, each carry-
ing a minos transposable element insertion in one of the
fly GBA orthologs. Insertion of minos in the CG31414
gene leads to translation of truncated GCase, lacking129 C-terminal amino acids (out of the 448 amino acids
of the predicted normal fly GCase protein). The minos
insertion in CG31148 leads to a truncated protein
lacking 34 C-terminal amino acids. Due to their close
proximity on chromosome 3, simple genetic manipula-
tions cannot be employed to create a chromosome with
both mutated genes. However, double heterozygous fly is
an authentic model for the GD carrier state in human.
We generated double heterozygous flies, which ex-
hibited ~30% decrease in GCase activity, as expected
(Figure 4A). We then tested possible activation of UPR
in these flies. The fly does not contain a CHOP homo-
log in its genome and UPR activation is measured by
elevation in mRNA of the BiP ortholog heat-shock
cognate 70–3 (Hsc-70-3 gene), in level of Xbp1 splicing
and in the level of phosphorylated eIF2α. We observed
a significant elevation in the level of Hsc-70-3 mRNA
and Xbp1 splicing in the double heterozygotes, as well
as in phosphorylation of eIF2α (Figure 4), compared to
WT flies. These results clearly point to existence of
UPR in carriers of mutations in the GBA orthologs of
Figure 3 Activation of UPR in carriers of GD mutations. A. RNA was isolated from skin fibroblasts that originated from carriers of GD
mutations, and the corresponding cDNA was used for quantitative RT-PCR with primers specific for human BiP or CHOP. GAPDH was used as a
normalizing control. B. cDNA, prepared as in (A), was subjected to RT-PCR, with primers specific for the spliced form of human Xbp1. GAPDH was
used as a normalizing control. C. The results (three different experiments) were quantified as explained in the legend to Figure 2 and the values
obtained for normal cells were considered 1. D. Protein lysates, prepared from the above-mentioned cells, were subjected to western blotting
and interaction with anti phosphorylated eIF2α antibodies (p-eIF2α). As a loading control, the blots were interacted with anti eIF2α antibodies.
E. The results (three different experiments) were quantified as explained in the legend to Figure 3B, and the values obtained for normal cells
were considered 1. There are two blots, each with a normal control. This is due to the fact that cell lysates were prepared at different times,
depending on the growth rate of the cell lines and, therefore, ran on different gels. Significance: * < 0.05; ** < 0.01; *** < 0.005. The genotypes for
B and D are shown in C and E, respectively.
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larva to pupa and from pupa to adult was found in the
double heterozygous animals, in comparison to WT
Drosophila (Figure 4E). This highlights the significance
of normal GCase during development and the deleteri-
ous effect of mutant GCase.
We also ectopically expressed the N370S or the L444P
human mutant GCase variants in the fly, using the Gal4/
UAS system. In this system the yeast Gal4 transcription
factor, expressed from a tissue specific Drosophila pro-
moter, is used to express a specific transgene (in our
case, the human normal or mutant mycHis tagged
GCase cDNAs) coupled to the yeast UAS. Thus, expres-
sion of the transgene depends on the specificity of the
promoter used for the expression of the Gal4 transcrip-
tion factor. We used daughterless-Gal4, which drives
ubiquitous expression of the transgene. We verified
expression of the transgene using western blotting and
interaction with anti myc antibody (Figure 5A). The
results showed expression of the normal human as well
as the mutant proteins in the transgenic flies. Incomparison to the normal human protein expressed in
the fly, the N370S or the L444P mutant variants
presented higher endo-H sensitivity (Figure 5A)
[21,29,30], illustrating the existence of ERAD of mutant
human GCase in the flies. The fraction of lysosomal
N370S human GCase, (endo-H resistant fraction, labeled
by black circles in Figure 5A) was higher than that of
L444P human GCase, as expected for these two muta-
tions and shown for endogenous human N370S and
L444P mutant GCase variants [21,29]. Furthermore, the
results (Figure 5B-D) demonstrated higher activation of
the UPR in flies expressing the mutant variants than
those expressing the WT human GCase. UPR was mea-
sured by increase in the mRNA levels of Hsc-70-3, in
the mRNA levels of spliced Xbp1 and in the levels of
phosphorylated eIF2α.
A significant defect in development from larva to pupa
and from pupa to adult was found in animals expressing
the human mutant GCase variants, in comparison to
animals expressing the WT human GCase (Figure 5E),
similar to the double heterozygous flies. This highlights
Figure 4 UPR activation in Drosophila carriers of mutant GBA orthologs. A. GCase activity was tested in protein lysates prepared from either
adult wild type (Canton S, WT) flies or from males and females of double heterozygous flies (Mi{ET1}CG31148,CG31414/CG31148,Mi{ET1}CG31414)
using 4-MUG as a substrate. Presented are results of three experiments. B. RNA was isolated from double heterozygous flies, and the cDNA
prepared from it was subjected to quantitative RT-PCR with primers specific for Drosophila Hsc-70-3 or for the spliced form of Drosophila Xbp1.
The results (three different experiments) were quantified as explained in the legend to Figure 1A, and the values obtained for WT flies were
considered 1. RP49 was used as a normalizing control. Dark box: WT flies; light box: double heterozygous flies. C. Protein lysates from double
heterozygous flies (Double hets.) were subjected to western blotting and interaction with anti phosphorylated eIF2α antibodies (p-eIF2α). D. The
results (three different experiments) were quantified as explained in the legend to Figure 2E and the values obtained for WT flies were
considered 1. Significance: * < 0.05; ** < 0.01. E. The number of larvae, (L3,) that survived to the pupal stage, and the number of adults that
eclosed was counted. The number of larvae taken for each experiment was 90.
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the fly leads to deleterious effects, regardless of the pres-
ence of endogenous WT GCase.
Locomotor dysfunction in flies expressing human mutant
GCase variant
An association has been found between GD patients and
carriers of GD mutations and PD. Thus, GD patients
and carriers of GD mutations are prone to develop PD
[31-55]. We used the Ddc-Gal4 driver in order to drive
specific expression of the human N370S and the L444P
GCase mutants in the dopaminergic/serotonergic neu-
rons of the fly. The locomotion (climbing) assay, com-
monly used for assaying behavior of flies expressing
familial Parkinson related proteins in their brain [56],was used to assess the neural dysfunction caused to the
flies due to expression of mutant GCase in the nervous
system. We monitored the climbing ability of the flies at
the age of 7, 12 and 22 days. Measurements, conducted
at the age of 22 days, revealed significant locomotion
dysfunction in both fly models for carriers of GD muta-
tions, namely, flies double heterozygotes in their two
GBA orthologs and flies transgenic for the N370S or the
L444P mutant human GCase variants (Figure 6).
Discussion
In this work we show that persistent presence of mutant
GCase activates the UPR, in humans and in Drosophila.
Several previous publications have already noticed
the existence of UPR in GD derived skin fibroblasts.
Figure 5 Activation of UPR in Drosophila expressing the human N370S or L444P mutant variants. A. Protein lysates were prepared from
10 flies expressing the human UAS-mycHisWTGCase, human UAS-mycHisN370SGCase, or human UAS-mycHisL444PGCase, driven by DaGal4.
Samples, containing 100 μg of protein, were subjected to overnight endo-H digestion, after which they were electrophoresed through SDS-PAGE
and the corresponding blot was interacted with anti GCase and anti actin antibodies. Total GCase amount was divided by that of actin at the
same lane and normalized to WT GCase, which was considered 100. The endo-H sensitive fraction before and after endo-H treatment, and the
endo-H resistant fraction were labeled for convenience, as follows: endo-H sensitive before treatment: * [Endo-Hs(−)]; endo-H sensitive after
treatment: # [Endo-Hs(+)]; endo-H resistant: • [Endo-Hr(+)]. B. RNA was isolated from the above-mentioned flies, and the cDNA prepared from it
was subjected to quantitative RT-PCR with the appropriate primers. RP49 was used as a normalizing control. The results (three different
experiments) were quantified as explained in the legend to Figure 3B and the values obtained for flies expressing normal human GCase were
considered 1. Significance: * < 0.05; ** < 0.01. C. Protein lysates, prepared from the above–mentioned flies, were subjected to western blotting and
interaction with anti phosphorylated eIF2α antibodies (p-eIF2α). As a loading control, the blot was interacted with anti eIF2α antibodies. D. The
results (three different experiments) were quantified as explained in the legend to Figure 3B and the values obtained for wild type flies were
considered 1. E. The number of larvae, (L3), that survived to the pupal stage, and the number of pupae that eclosed was counted. The number of
larvae taken for each experiment was 90.
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derived skin fibroblast line, a significant increase in
mRNA level of the UPR related genes ATF6, BiP and
Xbp1. This was accompanied by a concomitant increase
in the protein level of active ATF6, BiP and phospho-
rylated eIF2α [17]. Mu et al. reported on UPR activation
in cell lines that derived from GD patients homozygous
for the N370S and the L444P mutations [24]. In another
publication the efficacy of catechin in alleviating UPR in
one GD derived line (N370S/N370S) has been docu-
mented [18].
In the present work we show UPR activation in skin
fibroblasts derived from GD patients manifested by an
increase in mRNA and protein levels of BiP and CHOP,splicing of Xbp1 and phosphorylation of eIF2α. We also
show that in fibroblast lines derived from carriers of GD
mutations there is UPR as well. Interestingly, the 84GG
mutation is not expected to culminate in a mature
protein [6]. Since there is UPR in carriers of this
mutation, one has to assume that either the 84GG
mutant RNA participates in translation of a very short
peptide (26 amino acids long), shorter than the full
size leader of GCase (38 amino acids long), thereby
blocking ER entrance of newly synthesized proteins,
or the 84GG mRNA-bound polyribosomes block ER
entrance, thereby leading to development of ER stress
and, as a result, to UPR. These hypotheses will have
to be further tested.
Figure 6 Locomotion test in flies. A. Five vials, each containing flies expressing the human UAS-mycHiswtGCase, human UAS-mycHisN370SGCase,
or human UAS-mycHisL444P GCase, driven by the DdcGal4 driver, were analyzed for locomotion behavior. B. The same experiment as described in A
was performed using the WT and double heterozygous flies.
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Drosophila has become an important tool in studying
these phenomena. The short life span of the fly with the
sophisticated molecular and genetic tools for fast estab-
lishment of transgenic lines, and availability of deletions
and mutations in any chosen gene have made it an
attractive model, which allows fast screening and analyses
of large populations. We could recapitulate UPR in two fly
models: one corresponding to carriers of GD mutations
and the other involving transgenic flies expressing the
human N370S or the L444P mutant proteins.
All lysosomal enzymes are synthesized on ER bound
polyribosomes and upon their entry into the ER undergo
N-linked glycosylation and quality control, after which
they shuttle to the Golgi apparatus. Following further
modifications there, they are trafficked to the lysosomes.
Therefore, all mutant lysosomal enzymes are expected to
undergo ERAD and induce the UPR machinery. UPR
has already been documented in other lysosomal dis-
eases. Thus, in Fabry disease which results from muta-
tion in the α-galactosidase-A encoding gene (α-Gal-A)
and accumulation of the globotrioside Gb3, mutant vari-
ants undergo ERAD, which induces the UPR [57,58].
UPR has also been documented in skin fibroblasts from
patients suffering from ceroid lupofusinosis (CLN) 1, 2,
3, 6 and 8, as well as in cells of patients with GM1
gangliosidosis (suffering from reduced activity of β-
galactosidase), Tay Sachs disease (reduced activity of
β-hexosaminidase A) and Niemann Pick type C2 (muta-
tions in the NPC2 gene) [17]. Interestingly, in some
model systems for lysosomal diseases UPR was not reca-
pitulated. Farfel et al. [19] were unable to demonstrate
UPR in neuronal cells that derived from knockout mice,lacking the GBA gene, or in animals or cells, treated
with the GCase non-competitive inhibitor CBE. Lack of
UPR in both of these cases is likely due to the absence
of mutant GCase in the ER. Likewise, in NPC1-deficient
mice and in an NPC1 cell-based model, created by
knocking down the expression of NPC1 using RNA
interference, there was no UPR [59]. Again, in both
cases, no mutant protein was present in the ER to
induce the UPR machinery.
In recent years association has been elegantly demon-
strated between GD and PD, a neurodegenerative disease
affecting 1% of individuals over 60 years old. Thus, there
is a higher propensity among Type 1 GD patients and
among carriers of GD mutations to develop PD in
comparison to the non-GD population [31-55]. Brains of
carriers of GD mutations who develop PD display Lewy
bodies (LB) and loss of substantia nigra neurons [60].
Carriers of GBA mutations tend to have more cortical
LBs than those of non-carriers (82% versus 43%, res-
pectively) [61], suggesting that mutant GCase variants
promote α-synuclein aggregation directly. Cullen et al.
showed that expression of mutant human GCase, but
not that of the normal counterpart, led to increase in α-
synuclein accumulation in MES23.5, PC12, and HEK293
cell lines, arguing that mutant GCase has a direct role in
α-synuclein accumulation, and most probably, aggre-
gation [62].
Since carriers of GD mutations do not accumulate
GlcCer in their brain and its build-up has not been dem-
onstrated in brains of Type 1 GD patients, we raised the
possibility that ERAD of mutant GCase contributes to
the development of PD among GD patients and carriers
of GD mutations. We have shown that parkin interacts
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nation and proteasomal degradation [20]. We proposed
that this interaction between parkin and mutant GCase
leads to deleterious effect in dopaminergic cells caused
by the accumulation of parkin substrates, which are
potentially toxic. Our recent results (Bendikov-Bar and
Horowitz, unpublished) show that mutant GCase com-
petes with two known substrates of parkin, PARIS [63]
and ARTS [64], whose accumulation in cells leads to
apoptosis. PARIS is a transcription repressor of pero-
xisome proliferator-activated receptor gamma (PPARγ)
coactivator-1α (PGC-1α) expression. PGC-1α is a master
regulator of mitochondrial biogenesis [65]. Thus, PARIS
accumulation impedes mitochondria biogenesis. Inter-
estingly, PARIS accumulates in mouse models of parkin
inactivation and in PD patients’ brains [63]. ARTS is a
mitochondrial protein that initiates caspase activation,
upstream of cytochrome c release in the mitochondrial
apoptotic pathway [66].
We now extend our hypothesis for the role of mutant
GCase in the development of PD. We propose that
ERAD of mutant GCase leads to accumulation of parkin
substrates, some of which are deleterious, like PARIS
and ARTS. This accumulation leads to cell death. We
also assume that UPR, as part of the cellular ER stress,
induced by the persistent presence of mutant GCase in
the ER, leads to cellular death. Therefore, both, ERAD of
mutant GCase and UPR contribute to dopaminergic cell
death and development of PD. It still remains to be
tested whether and how mutant GCase leads to aggrega-
tion of α-synuclein.
In the present work we show that expression of the
mutant fly orthologs of GBA or expression of human
mutant N370S or L444P proteins leads to death at early
stages of the fly development. The flies expressing
mutant GCase in the dopaminergic/serotonergic cells
develop locomotion dysfunction, reminiscent of PD.
This is the first animal model in which carriers of GD
mutations develop parkisonian signs.
In a recent publication, parkin insolubility was asso-
ciated with lack of degradation of ubiquitinated proteins
and accumulation of α-synuclein and parkin in autopha-
gosomes, suggesting autophagic defects in PD [67]. To
test parkin’s role in mediating autophagic clearance, the
authors used lentiviral gene transfer to express human
wild type or mutant parkin (T240R) with α-synuclein in
the rat striatum. Lentiviral expression of α-synuclein
led to accumulation of autophagic vacuoles, while co-
expression of parkin with α-synuclein facilitated auto-
phagic clearance. Expression of parkin loss-of-function
mutation did not affect autophagic clearance. Taken
together, the data suggested that functional parkin
regulates autophagosome clearance. It is possible, and
remains to be proven, that the interaction betweenparkin and mutant GCase variants in dopaminergic
cells attenuates normal autophagy, which leads to α-
synuclein aggregation.
Our results strongly indicate a direct association
between mutant GCase and development of Parkinsonian
signs in the fly. However, there is another paradigm,
arguing that insufficient lysosomal mutant GCase activity
leads to substrate accumulation (GlcCer or gluco-
sylsphingosine), α-synuclein aggregation, block in traffick-
ing of GCase to lysosomes and development of PD
[60,62,68-70]. Thus, Sardi et al. showed that in brain
sections derived from 12 months old D409V homozygous
mice (but not from D409V heterozygous animals) there
are α-synuclein and ubiquitin aggregates in the hippocam-
pus, cerebral cortex and cerebellum. Memory deficits were
detected in these mice at 6 months of age [68]. Adminis-
tration of normal enzyme to the brain using gene therapy
with an AAV derived vector, expressing a normal human
GBA cDNA, significantly reduced the aggregation of
ubiquitin and α-synuclein and ameliorated the memory
deficit [71].
Development of PD in carriers of GD mutations
implies that the presence of a mutant GBA allele is a
dominant predisposing factor. This is a unique case of
an autosomal recessive metabolic disease with a domi-
nant element, namely the tendency of carriers of GD
mutations to develop PD.
Dominance results either from haploinsufficiency or
from gain of function. If haploinsufficiency accounts for
the development of PD in carriers of GD mutations, it
implies insufficient GCase activity in the dopaminergic
neurons. Why is it not manifested in macrophages, in
which case the disease would have been dominant? If,
alternatively, the dominance results from gain of func-
tion, then its development depends on accumulation of
enough deleterious product (mutant GCase, in our case),
as in the case of Alzheimer disease, which displays age
dependent accumulation of β-amyloid and tau, or
Huntington disease, which exhibits accumulation of
huntingtin [72-74]. Our results suggest the gain of func-
tion alternative.Conclusions
In this study we show that UPR is activated in GD patients
as well as in carriers of GD mutations. In Drosophila
models for carriers of different GD mutations, UPR is acti-
vated as well, and locomotion deficits are observed in the
aging flies as a result of the presence of mutant GCase.Consent
Written informed consent was obtained from the
patients for publication of this paper.
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Additional file 1: Figure S1. CBE treatment does not induce UPR. A. To
test the effect of substrate accumulation on induction of the UPR
machinery, normal skin fibroblasts were treated with 200 mM of the
GCase non-competitive inhibitor, CBE (Sigma-Aldrich, Israel) for 10 days.
Enzymatic activity was tested after a day and 10 days of treatment, using
4-MUG as a substrate. B. Following 10 days of CBE treatment RNA was
prepared from the cells and activation of UPR was tested by following
CHOP and BiP mRNA, using quantitative RT-PCR with primers specific for
human BiP (Human-GRP78-RT-F and Human-GRP78-RT-R, Table 1) or
CHOP (Human-CHOP-RT-F and Human-CHOP-RT-R, Table 1). GAPDH was
used as a normalizing control (amplified with primers: Human-GAPDH-RT-
F and Human-GAPDH-RT-R, Table 1). As control for UPR activation, cells
were treated for 3 hours with 150 nM of Thapsigargin (Sigma Aldrich,
Israel), after which RNA was prepared and used for quantitative RT-PCR.
Significance: * < 0.05; ** < 0.01. Dark box: CHOP; Light box: BiP.
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